← ANALYST RATINGS · TIPRANKS
Eli Lilly & Co (LLY): analyst forecast and price target
Analyst consensus
Strong Buy20 Buy2 Hold1 Sell
Ratings of 23 analysts in the last 3 months12-month forecast
Based on 23 price targets given in the last 3 months, the average target is $1,366, the highest $1,600, the lowest $940. The average is +8.7% from the last price of $1,257.
Analyst ratings 26
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Trung Huynh★★★★★★★★★★#475 · hits 76% · avg +21.9% | RBC Capital | $1,500 | Buy | +19.3% | Reiterated | 16.10.26on TipRanks 21:45 | after the close | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $1,330 | Buy | +5.8% | Reiterated | 15.10.26on TipRanks 07:26 | +3.3%next day +1.5% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $1,400 | Buy | +11.4% | Reiterated | 12.10.26on TipRanks 08:55 | +0.3%next day −1.4% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $1,600 | Buy | +27.3% | Reiterated | 12.10.26on TipRanks 07:45 | +0.3%next day −1.4% | ↗ |
| Emily Field★★★★★★★★★★#5009 · hits 45% · avg +1.9% | Barclays | $1,400 | Buy | +11.4% | Reiterated | 12.10.26on TipRanks 05:07 | +0.3%next day −1.4% | ↗ |
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | $1,500 | Buy | +19.3% | Reiterated | 09.10.26on TipRanks 10:15 | +0.2%next day +0.3% · 5 days +8.6% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $1,344 → $1,341−0.2% | Buy | +6.7% | Reiterated | 09.10.26on TipRanks 06:25 | +0.2%next day +0.3% · 5 days +8.6% | ↗ |
| Carter Gould★★★★★★★★★★#2194 · hits 53% · avg +6.3% | Cantor Fitzgerald | $1,410 → $1,440+2.1% | Buy | +14.6% | Assigned | 08.10.26on TipRanks 07:10 | −1.2%next day +0.2% · 5 days +7.3% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $1,430 | Buy | +13.8% | Reiterated | 07.10.26on TipRanks 08:15 | +2.9%next day −1.2% · 5 days +2.7% | ↗ |
| Steve Scala★★★★★★★★★★#1275 · hits 63% · avg +10.5% | TD Cowen | $1,250 | Buy | −0.6% | Reiterated | 01.10.26on TipRanks 11:45 | −0.8%next day −1.3% · 5 days +0.4% | ↗ |
| Srikripa Devarakonda★★★★★★★★★★#200 · hits 62% · avg +26.3% | Truist Financial | — | Buy | — | Reiterated | 01.10.26on TipRanks 11:40 | −0.8%next day −1.3% · 5 days +0.4% | ↗ |
| Asad Haider★★★★★★★★★★#1137 · hits 82% · avg +22.7% | Goldman Sachs | $1,367 → $1,371+0.3% | Buy | +9.1% | Reiterated | 30.09.26on TipRanks Oct 1 09:45 | −2.1%next day −0.8% · 5 days +0.8% | ↗ |
| Name not given | — | $1,035 | Hold | −17.7% | Reiterated | 23.09.26on TipRanks Sep 29 08:45 | −0.9%next day +2.8% · 5 days +1.2% | |
| Umer Raffat★★★★★★★★★★#2336 · hits 50% · avg +9.4% | Evercore ISI | — | Hold | — | Reiterated | 23.09.26on TipRanks 09:08 | −0.9%next day +2.8% · 5 days +1.2% | ↗ |
| Akash Tewari★★★★★★★★★★#649 · hits 57% · avg +13.5% | Jefferies | $1,440 | Buy | +14.6% | Reiterated | 22.09.26on TipRanks 09:25 | +0.5%next day −0.9% · 5 days +2.4% | ↗ |
| Seamus Fernandez★★★★★★★★★★#129 · hits 66% · avg +30.6% | Guggenheim | $1,273 → $1,284+0.9% | Buy | +2.1% | Reiterated | 17.09.26on TipRanks Sep 18 07:10 | +0.2%next day −0.1% · 5 days +1.7% | ↗ |
| David Risinger★★★★★★★★★★#64 · hits 65% · avg +33.1% | Leerink Partners | — | Buy | — | Reiterated | 16.09.26on TipRanks Sep 17 05:55 | +0.6%next day +0.2% · 5 days −0.9% | ↗ |
| Kerry Holford★★★★★★★★★★#2798 · hits 58% · avg +8.7% | Berenberg Bank | $1,220 → $1,400+14.8% | Buy | +11.4% | Upgrade | 14.09.26on TipRanks Sep 15 04:40 | +2.5%next day +0.3% · 5 days +0.4% | ↗ |
| Rajesh Kumar★★★★★★★★★★#1587 · hits 62% · avg +14.5% | HSBC | $850 → $940+10.6% | Sell | −25.2% | Reiterated | 10.09.26on TipRanks 06:30 | +0.5%next day −1.5% · 5 days +2.0% | ↗ |
| Courtney Breen★★★★★★★★★★#1339 · hits 85% · avg +18.9% | Bernstein | $1,385 | Buy | +10.2% | Reiterated | 31.08.26on TipRanks Sep 1 07:50 | −1.2%next day +1.0% · 5 days −2.7% | ↗ |
| Nico Chen★★★★★★★★★★#2913 · hits 59% · avg +9.8% | DBS | $1,550 | Buy | +23.3% | Reiterated | 25.08.26on TipRanks 03:00 | −1.4%next day −3.6% · 5 days −5.4% | ↗ |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $1,420 → $1,363−4.0% | Buy | +8.4% | Reiterated | 06.08.26on TipRanks 10:05 | — | |
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $1,426 → $1,369−4.0% | Buy | +8.9% | Reiterated | 06.08.26on TipRanks 10:05 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $1,335 → $1,287−3.6% | Buy | +2.4% | Upgrade | 06.08.26on TipRanks 10:05 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $1,438 → $1,357−5.6% | Buy | +8.0% | Reiterated | 06.08.26on TipRanks 10:05 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $1,401 → $1,322−5.6% | Buy | +5.2% | Reiterated | 06.08.26on TipRanks 10:05 | — | |
| AI PerPlexity Drug Manufacturers - GeneralPerPlexity SonarPro | TipRanks - PerPlexity | $1,438 → $1,375−4.4% | Buy | +9.4% | Reiterated | 06.08.26on TipRanks 10:05 | — | |
| Louise Chen★★★★★★★★★★#1899 · hits 52% · avg +5.9% | Scotiabank | $1,300 | Buy | +3.4% | Reiterated | 06.08.26on TipRanks 07:55 | +2.0%next day −1.1% · 5 days +0.2% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $1,425 | Buy | +13.4% | Reiterated | 05.08.26on TipRanks Aug 6 06:55 | +5.1%next day +2.0% · 5 days +4.0% | ↗ |
| Alexandria Hammond★★★★★★★★★★#7870 · hits 50% · avg +0.6% | Wolfe Research | $1,325 → $1,350+1.9% | Buy | +7.4% | Reiterated | 21.05.26on TipRanks 09:30 | +2.0%next day +1.8% · 5 days +4.2% | ↗ |
| James Shin★★★★★★★★★★#4468 · hits 57% · avg +7.3% | Deutsche Bank | $1,285 | Buy | +2.2% | Reiterated | 07.05.26on TipRanks 08:50 | −0.9%next day −3.5% · 5 days +1.0% | ↗ |
| Narumi Nakagiri★★★★★★★★★★#5254 · hits 64% · avg +9.1% | Daiwa | $1,230 | Buy | −2.2% | Upgrade | 16.12.25on TipRanks 05:40 | −0.5%next day −0.1% · 5 days 0.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Eli Lilly & Co
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $1,364 at a price of $1,157 (+17.9%); now: $1,366 at $1,257 (+8.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 3 | 2 | 0 | 0 | 0 |
| Buy | 85 | 84 | 76 | 70 | 66 | 56 |
| Hold | 2 | 3 | 3 | 4 | 5 | 4 |
| Sell | 2 | 0 | 0 | 0 | 1 | 1 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $5.65 (from $4.65 to $7.27). Last quarter: $8.38.
Sales
Next quarter’s sales estimate — $22.5B (from $21.5B to $23.8B). Last quarter: $23.0B.
Best top-analyst consensus in the sector · Healthcare
About Eli Lilly & Co
- CEO: David A. Ricks
- Employees: 50,000
- Lilly Corporate Center, Indianapolis, IN, 46285, US
- www.lilly.com
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for
Data from the stock’s TipRanks forecast page, read 14 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗